UNSPSC 51182436: Tiludronic acid

This classification denotes a bone resorption inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PNS59HP4Y. European Medicines Agency schedules Tiludronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11060MIG. Tiludronic acid generally arises in the molecular formula C7H9CLO6P2S.

The term TILUDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) Most nations schedule tiludronic acid under HS 29309085 and SITC 51549. As of Q4 2014, TILUDRONIC ACID remains the US FDA Preferred Term for this commodity. Tiludronic acid bears US NLM identifiers UMLS ID C0043611 and NCI Concept Code C72091. SMILES: Clc1ccc(SC(P(=O)(O)O)P(=O)(O)O)cc1.

UNSPSC 51182436 Tiludronic acid is a Commodity code that encompasses pharmaceutical active ingredients and finished dosage forms supplied through state and local cooperative purchasing vehicles and multistate pharmaceutical procurement programs. State and local governments procure under this code primarily through group purchasing organizations and cooperative purchasing alliances that aggregate demand across multiple jurisdictions to negotiate volume-based pricing on branded and generic pharmaceuticals, including specialty medications, biologics, and over-the-counter products. The issuing bodies are state departments of administration, multistate cooperative purchasing alliances, and their member jurisdictions—including state agencies, counties, cities, and special-purpose health and human services districts that rely on cooperative contracts to stock pharmacy inventories, clinical supplies, and medication distribution systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three wholesalers, and provide pricing in flat price, net price, or WAC-minus formats. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026 and a two-year initial term. The RFP weights price competitiveness at 75 percent, with the remainder distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must carry commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.